Foreign-Trade Zone 99 - Wilmington, Delaware, Expansion of Subzone and Manufacturing Authority Subzone 99D, AstraZeneca Pharmaceuticals LP (Pharmaceutical Products), Newark, Delaware, 30079-30080 [05-10461]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 100 / Wednesday, May 25, 2005 / Notices
in Federally Assisted Programs of the
Department of Agriculture—Effectuation
of Title VI of the Civil Rights Act of
1964.
Certain OMB circulars also apply to
USDA grant programs and must be
followed by a grantee under this
program. The policies, guidance, and
requirements of the following, or their
successors, may apply to the award,
acceptance and use of assistance under
this program and to the remedies for
noncompliance, except when
inconsistent with the provisions of the
Agriculture, Rural Development and
Related Agencies Appropriations Acts,
other Federal statutes or the provisions
of this NOFA:
• OMB Circular No. A–87 (Cost
Principles Applicable to Grants,
Contracts and Other Agreements with
State and Local Governments);
• OMB Circular A–21 (Cost Principles
for Education Institutions);
• OMB Circular No. A–122 (Cost
Principles for Nonprofit Organizations);
• OMB Circular A–133 (Audits of
States, Local Governments, and NonProfit Organizations);
• 7 CFR part 3015 (Uniform Federal
Assistance Regulations);
• 7 CFR part 3016 (Uniform
Administrative Requirements for Grants
and Cooperative Agreements to State,
Local, and Federally recognized Indian
tribal governments);
• 7 CFR part 3017 (Governmentwide
debarment and suspension (nonprocurement) and governmentwide
requirements for drug-free workplace
(grants));
• 7 CFR part 3018 (New restrictions
on Lobbying);
• 7 CFR part 3019 (Uniform
administrative requirements for grants
and Agreements with Institutions of
Higher Education, Hospitals, and other
Non-Profit Organizations); and
• 7 CFR part 3052 (Audits of States,
local governments, and non-profit
organizations).
Compliance with additional OMB
Circulars or government-wide
regulations may be specified in the grant
agreement.
3. Reporting
The grantee will be required to
provide periodic financial and
performance reports under USDA grant
regulations and RUS rules and to submit
a final project performance report. The
nature and frequency of required reports
are established in USDA grant
regulations and the project-specific
grant agreements.
VII. Agency Contact
The Agency Contact for this grant
announcement is Karen Larsen,
VerDate jul<14>2003
17:52 May 24, 2005
Jkt 205001
Management Analyst, U.S. Department
of Agriculture, Rural Utilities Service,
Electric Program, 1400 Independence
Avenue, SW., STOP 1560, Room 5165
South Building, Washington, DC 20250–
1560. Telephone 202–720–9545, Fax
202–690–0717, e-mail
Karen.Larsen@usda.gov.
Dated: May 18, 2005.
Curtis M. Anderson,
Acting Administrator, Rural Utilities Service.
[FR Doc. 05–10378 Filed 5–24–05; 8:45 am]
BILLING CODE 3410–15–P
DEPARTMENT OF COMMERCE
Foreign–Trade Zones Board
[Docket 22–2005]
Foreign–Trade Zone 99 - Wilmington,
Delaware, Expansion of Subzone and
Manufacturing Authority Subzone 99D,
AstraZeneca Pharmaceuticals LP
(Pharmaceutical Products), Newark,
Delaware
An application has been submitted to
the Foreign–Trade Zones Board (the
Board) by the Delaware Economic
Development Office, grantee of FTZ 99,
requesting to expand the subzone and
the scope of manufacturing authority
under zone procedures within Subzone
99D, at the AstraZeneca
Pharmaceuticals LP (AstraZeneca)
facility in Newark, Delaware. It was
formally filed on May 17, 2005.
Subzone 99D was approved by the
Board in 1994 at AstraZeneca’s plant (2
bldgs. on 156 acres/520,700 sq. ft.)
located at 587 Old Baltimore Pike,
Newark, Delaware, some 10 miles west
of Wilmington. The facility (530
employees) is used to produce and/or
distribute a wide range of
pharmaceuticals, with specific authority
granted for the manufacture of several
products under zone procedures (Board
Order 717, 12/02/94).
Subzone 99D is currently requesting
to expand the subzone at the existing
facility (Site 1) to include additions to
existing buildings (totaling 114,100 sq.
ft.) and to include another site (Site 2)
for the manufacture of clinical trial
products. AstraZeneca is also requesting
to include in its scope of authority
general categories of inputs and final
products that it may produce under
zone procedures in the future.
Proposed Site 2 (30 buildings,
3,226,805 sq. ft. (526,552 mfg. sq. ft.) on
163 acres, which includes a potential
expansion of 7 buildings totaling 1,154,
298 sq. ft. (318,548 mfg. sq. ft.)) is
located at 1800 Concord Pike,
Wilmington, Delaware, some 20 miles
PO 00000
Frm 00024
Fmt 4703
Sfmt 4703
30079
from Site 1. It will be used to produce
finished dose pharmaceutical
formulations of clinical trial products
(HTSUS 3004.90, duty–free). Materials
sourced from abroad represent 90 to 95
percent of all materials used in
production proposed for zone
procedures. Inverted tariff savings will
initially result from the following bulk
active ingredients, all subject to a 6.5%
duty rate: AZD 0328 (HTSUS
2934.99.9000), AZD 5455 (HTSUS
2933.39.9100) and AZD 4522 (HTSUS
2935.00.6000). Finished dose products
will be transferred to Site 1 for
packaging and shipping.
The application also requests
authority to include a broad range of
inputs and pharmaceutical final
products that it may produce under FTZ
procedures in the future. (New major
activity in these inputs/products could
require review by the FTZ Board.)
General HTSUS categories of inputs
include: 1108, 1212, 1301, 1302, 1515,
1516, 1520, 1521, 1702, 1905, 2106,
2207, 2302, 2309, 2501, 2508, 2510,
2519, 2520, 2526, 2710, 2712, 2807,
2809, 2811, 2814, 2815, 2816, 2817,
2821, 2823, 2825, 2826, 2827, 2829,
2831, 2832, 2833, 2835, 2836, 2837,
2839, 2840, 2841, 2842, 2843, 2844,
2846, 2851, 2901, 2902, 2903, 2904
(except for HTS 2904.20.5000), 2905,
2906, 2907, 2908, 2909, 2910, 2911,
2912, 2913, 2914, 2915, 2916, 2917,
2918, 2919, 2920, 2921, 2922, 2923,
2924, 2925, 2926, 2927, 2928, 2929,
2930, 2931, 2932, 2933, 2934, 2935,
2936, 2937, 2938, 2939, 2940, 2941,
2942, 3001, 3002, 3003, 3004, 3005,
3006, 3102, 3104, 3301, 3302, 3305,
3401, 3402, 3403, 3404, 3502, 3503,
3505, 3506, 3507, 3802, 3804, 3808,
3809, 3815, 3822, 3823, 3824, 3901,
3906, 3910, 3911, 3912, 3913, 3914,
3915, 3919, 3920, 3921, 3923, 4016,
(4202.92.1000, 4202.92.9060,
4202.99.1000, 4202.99.5000 (plastic
only)), 4817, 4819, 4901, 4902, 5403,
7010, 7607, 8004, 8104, 8309, 8481,
9018, and 9602. The duty rates on these
products range from duty–free to 17%.
Final products that may be produced
from the inputs listed above include
these general HTSUS categories: 2302,
2309, 2902, 2903, 2904, 2905, 2906,
2907, 2909, 2910, 2912, 2913, 2914,
2915, 2916, 2917, 2918, 2920, 2921,
2922, 2923, 2924, 2925, 2926, 2928,
2930, 2931, 2932, 2933, 2934, 2935,
2936, 2937, 2938, 2939, 2941, 2942,
3001, 3002, 3003, 3004, 3006, 3802,
3804, 3808, 3809, 3824, 3910, 3911,
3912, 3913, and 3914. The duty rates on
these products range from duty–free to
7.5%.
Zone procedures would exempt
AstraZeneca from Customs duty
E:\FR\FM\25MYN1.SGM
25MYN1
30080
Federal Register / Vol. 70, No. 100 / Wednesday, May 25, 2005 / Notices
payments on foreign materials used in
production for export. On domestic
shipments, the company would be able
to defer Customs duty payments on
foreign materials, and to choose the
duty rate that applies to finished
products (duty–free) instead of the rates
otherwise applicable to the foreign
input materials (6.5%). The application
indicates that the savings from zone
procedures would help improve
AstraZeneca’s international
competitiveness.
In accordance with the Board’s
regulations, a member of the FTZ staff
has been designated examiner to
investigate the application and report to
the Board.
Public comment is invited from
interested parties. Submissions (original
and 3 copies) shall be addressed to the
Board’s Executive Secretary at one of
the following addresses:
1. Submissions Via Express/Package
Delivery Services: Foreign–TradeZones Board, U.S. Department of
Commerce, Franklin Court Building
- Suite 4100W, 1099 14th St. NW,
Washington, D.C. 20005; or
2. Submissions Via the U.S. Postal
Service: Foreign–Trade-Zones
Board, U.S. Department of
Commerce, FCB - Suite 4100W,
1401 Constitution Ave. NW,
Washington, D.C. 20230.
The closing period for their receipt is
July 25, 2005. Rebuttal comments in
response to material submitted during
the foregoing period may be submitted
during the subsequent 15-day period (to
August 8, 2005).
A copy of the application and
accompanying exhibits will be available
for public inspection at the Office of the
Foreign–Trade Zones Board’s Executive
Secretary at address Number 1 listed
above, and at the U.S. Department of
Commerce Export Assistance Center,
The Curtis Center - Suite 580, West 601
Walnut Street - Independence Square
West, Philadelphia, PA 19106–3304.
Dated: May 19, 2005.
Dennis Puccinelli,
Executive Secretary.
[FR Doc. 05–10461 Filed 5–24–05; 8:45 am]
BILLING CODE 3510–DS–S
VerDate jul<14>2003
17:52 May 24, 2005
Jkt 205001
DEPARTMENT OF COMMERCE
Foreign–Trade Zones Board
[Docket 23–2005]
Foreign–Trade Zone 7 Mayaguez,
Puerto Rico, Application for Subzone,
Abbott Laboratories (Pharmaceutical
Products), Barceloneta, Puerto Rico
An application has been submitted to
the Foreign–Trade Zones (FTZ) Board
(the Board) by the Puerto Rico Industrial
Development Corporation, grantee of
FTZ 7, requesting special–purpose
subzone status for the pharmaceutical
manufacturing facilities of Abbott
Pharmaceuticals PR LTD. (APPR),
Abbott Health Products, Inc. (AHP), and
Abbott Biotechnology LTD (ABL),
subsidiaries of Abbott Laboratories
(Abbott), located in Barceloneta, Puerto
Rico. The application was submitted
pursuant to the Foreign–Trade Zones
Act, as amended (19 U.S.C. 81a–81u),
and the regulations of the Board (15 CFR
part 400). It was formally filed on May
17, 2005.
The proposed subzone (123 buildings
of 2,151,957 square feet (approx. 90%
mfg. sq. ft.) on 276 acres, with a possible
expansion of 34 buildings of 2,330,579
sq. ft.) is comprised of one site located
at Road No. 2, Km 58.0, Barceloneta,
Puerto Rico. The Abbott facility (2,200
employees) manufactures, tests,
packages, and warehouses
pharmaceutical and diagnostic
products, activities which it is
proposing to perform under zone
procedures.
It will be used to produce finished
dose pharmaceutical formulations and
diagnostic products. Initially, the
company is proposing to produce the
antibiotics, clarythromycin and
erythromycin; and Depakote/ a
treatment for epilepsy, migraine and
bipolar disorder, under zone
procedures. Materials sourced from
abroad represent 5–10 percent of the
value of the finished products
manufactured under the proposed
primary scope. Inverted tariff savings
will initially result from the following
ingredients: Beta Carb (HTSUS
2917.19.7050), hexamethyldisilozane
(HTSUS 2931.00.9010), and
hypromellose phtalate (HTSUS
3912.90.0090). Some 60 to 80 percent of
the proposed production under zone
procedures will be exported.
The application also requests
authority to include a broad range of
inputs and pharmaceutical final
products that it may produce under FTZ
procedures in the future. (New major
activity in these inputs/products could
require review by the FTZ Board.)
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
General HTSUS categories of inputs
include: 1108, 1212, 1301, 1302, 1515,
1516, 1520, 1521, 1702, 1905, 2106,
2207, 2302, 2309, 2501, 2508, 2510,
2519, 2520, 2526, 2710, 2712, 2807,
2809, 2811, 2814, 2815, 2816, 2817,
2821, 2823, 2825, 2826, 2827, 2829,
2831, 2832, 2833, 2835, 2836, 2837,
2839, 2840, 2841, 2842, 2844, 2846,
2851, 2901, 2902, 2903, 2904 (except for
2904.20.5000), 2905, 2906, 2907, 2908,
2909, 2910, 2911, 2912, 2913, 2914,
2915, 2916, 2917, 2918, 2919, 2920,
2921, 2922, 2923, 2924, 2925, 2926,
2927, 2928, 2929, 2930, 2931, 2932,
2933, 2934, 2935, 2936, 2937, 2938,
2939, 2940, 2941, 2942, 3001, 3002,
3003, 3004, 3005, 3006, 3102, 3104,
3301, 3302, 3305, 3401, 3402, 3403,
3404, 3502, 3503, 3505, 3506, 3507,
3802, 3804, 3808, 3809, 3815, 3822,
3823, 3824, 3906, 3910, 3911, 3912,
3913, 3914, 3915, 3919, 3920, 3921,
3923, 4016, (4202.92.1000,
4202.92.9060, 4202.99.1000,
4202.99.5000 (plastic only)), 4817, 4819,
4901, 4902, 7010, 7607, 8004, 8104,
8309, 8481, 9018, 9602. Duty rates for
these materials range from duty–free to
17%.
Final products that may be produced
from the inputs listed above include
these general HTSUS categories: 2302,
2309, 2825, 2902, 2903, 2904, 2905,
2906, 2907, 2909, 2910, 2912, 2913,
2914, 2915, 2916, 2917, 2918, 2920,
2921, 2922, 2924, 2925, 2926, 2928,
2930, 2931, 2932, 2933, 2934, 2935,
2936, 2937, 2938, 2939, 2940, 2941,
2942, 3001, 3002, 3003, 3004, 3006,
3503, 3507, 3802, 3804, 3808, 3809,
3824, 3910, 3911, 3912, 3913, 3914 and
9018. Duty rates for these products
range from duty–free to 7.5%.
Zone procedures would exempt
Abbott from Customs duty payments on
foreign materials used in production for
export (some 60–80% of shipments). On
domestic shipments, the company
would be able to defer Customs duty
payments on foreign materials, and to
choose the duty rate that applies to
finished products (duty–free) instead of
the rates otherwise applicable to the
foreign input materials (3.7% - 5.2%).
The application indicates that the
savings from zone procedures would
help improve Abbott’s international
competitiveness.
In accordance with the Board’s
regulations, a member of the FTZ staff
has been designated examiner to
investigate the application and report to
the Board.
Public comment is invited from
interested parties. Submissions (original
and 3 copies) shall be addressed to the
Board’s Executive Secretary at one of
the following addresses:
E:\FR\FM\25MYN1.SGM
25MYN1
]]>Agencies
[Federal Register Volume 70, Number 100 (Wednesday, May 25, 2005)]
[Notices]
[Pages 30079-30080]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-10461]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[Docket 22-2005]
Foreign-Trade Zone 99 - Wilmington, Delaware, Expansion of
Subzone and Manufacturing Authority Subzone 99D, AstraZeneca
Pharmaceuticals LP (Pharmaceutical Products), Newark, Delaware
An application has been submitted to the Foreign-Trade Zones Board
(the Board) by the Delaware Economic Development Office, grantee of FTZ
99, requesting to expand the subzone and the scope of manufacturing
authority under zone procedures within Subzone 99D, at the AstraZeneca
Pharmaceuticals LP (AstraZeneca) facility in Newark, Delaware. It was
formally filed on May 17, 2005.
Subzone 99D was approved by the Board in 1994 at AstraZeneca's
plant (2 bldgs. on 156 acres/520,700 sq. ft.) located at 587 Old
Baltimore Pike, Newark, Delaware, some 10 miles west of Wilmington. The
facility (530 employees) is used to produce and/or distribute a wide
range of pharmaceuticals, with specific authority granted for the
manufacture of several products under zone procedures (Board Order 717,
12/02/94).
Subzone 99D is currently requesting to expand the subzone at the
existing facility (Site 1) to include additions to existing buildings
(totaling 114,100 sq. ft.) and to include another site (Site 2) for the
manufacture of clinical trial products. AstraZeneca is also requesting
to include in its scope of authority general categories of inputs and
final products that it may produce under zone procedures in the future.
Proposed Site 2 (30 buildings, 3,226,805 sq. ft. (526,552 mfg. sq.
ft.) on 163 acres, which includes a potential expansion of 7 buildings
totaling 1,154, 298 sq. ft. (318,548 mfg. sq. ft.)) is located at 1800
Concord Pike, Wilmington, Delaware, some 20 miles from Site 1. It will
be used to produce finished dose pharmaceutical formulations of
clinical trial products (HTSUS 3004.90, duty-free). Materials sourced
from abroad represent 90 to 95 percent of all materials used in
production proposed for zone procedures. Inverted tariff savings will
initially result from the following bulk active ingredients, all
subject to a 6.5% duty rate: AZD 0328 (HTSUS 2934.99.9000), AZD 5455
(HTSUS 2933.39.9100) and AZD 4522 (HTSUS 2935.00.6000). Finished dose
products will be transferred to Site 1 for packaging and shipping.
The application also requests authority to include a broad range of
inputs and pharmaceutical final products that it may produce under FTZ
procedures in the future. (New major activity in these inputs/products
could require review by the FTZ Board.) General HTSUS categories of
inputs include: 1108, 1212, 1301, 1302, 1515, 1516, 1520, 1521, 1702,
1905, 2106, 2207, 2302, 2309, 2501, 2508, 2510, 2519, 2520, 2526, 2710,
2712, 2807, 2809, 2811, 2814, 2815, 2816, 2817, 2821, 2823, 2825, 2826,
2827, 2829, 2831, 2832, 2833, 2835, 2836, 2837, 2839, 2840, 2841, 2842,
2843, 2844, 2846, 2851, 2901, 2902, 2903, 2904 (except for HTS
2904.20.5000), 2905, 2906, 2907, 2908, 2909, 2910, 2911, 2912, 2913,
2914, 2915, 2916, 2917, 2918, 2919, 2920, 2921, 2922, 2923, 2924, 2925,
2926, 2927, 2928, 2929, 2930, 2931, 2932, 2933, 2934, 2935, 2936, 2937,
2938, 2939, 2940, 2941, 2942, 3001, 3002, 3003, 3004, 3005, 3006, 3102,
3104, 3301, 3302, 3305, 3401, 3402, 3403, 3404, 3502, 3503, 3505, 3506,
3507, 3802, 3804, 3808, 3809, 3815, 3822, 3823, 3824, 3901, 3906, 3910,
3911, 3912, 3913, 3914, 3915, 3919, 3920, 3921, 3923, 4016,
(4202.92.1000, 4202.92.9060, 4202.99.1000, 4202.99.5000 (plastic
only)), 4817, 4819, 4901, 4902, 5403, 7010, 7607, 8004, 8104, 8309,
8481, 9018, and 9602. The duty rates on these products range from duty-
free to 17%.
Final products that may be produced from the inputs listed above
include these general HTSUS categories: 2302, 2309, 2902, 2903, 2904,
2905, 2906, 2907, 2909, 2910, 2912, 2913, 2914, 2915, 2916, 2917, 2918,
2920, 2921, 2922, 2923, 2924, 2925, 2926, 2928, 2930, 2931, 2932, 2933,
2934, 2935, 2936, 2937, 2938, 2939, 2941, 2942, 3001, 3002, 3003, 3004,
3006, 3802, 3804, 3808, 3809, 3824, 3910, 3911, 3912, 3913, and 3914.
The duty rates on these products range from duty-free to 7.5%.
Zone procedures would exempt AstraZeneca from Customs duty
[[Page 30080]]
payments on foreign materials used in production for export. On
domestic shipments, the company would be able to defer Customs duty
payments on foreign materials, and to choose the duty rate that applies
to finished products (duty-free) instead of the rates otherwise
applicable to the foreign input materials (6.5%). The application
indicates that the savings from zone procedures would help improve
AstraZeneca's international competitiveness.
In accordance with the Board's regulations, a member of the FTZ
staff has been designated examiner to investigate the application and
report to the Board.
Public comment is invited from interested parties. Submissions
(original and 3 copies) shall be addressed to the Board's Executive
Secretary at one of the following addresses:
1. Submissions Via Express/Package Delivery Services: Foreign-
Trade-Zones Board, U.S. Department of Commerce, Franklin Court Building
- Suite 4100W, 1099 14th St. NW, Washington, D.C. 20005; or
2. Submissions Via the U.S. Postal Service: Foreign-Trade-Zones
Board, U.S. Department of Commerce, FCB - Suite 4100W, 1401
Constitution Ave. NW, Washington, D.C. 20230.
The closing period for their receipt is July 25, 2005. Rebuttal
comments in response to material submitted during the foregoing period
may be submitted during the subsequent 15-day period (to August 8,
2005).
A copy of the application and accompanying exhibits will be
available for public inspection at the Office of the Foreign-Trade
Zones Board's Executive Secretary at address Number 1 listed above, and
at the U.S. Department of Commerce Export Assistance Center, The Curtis
Center - Suite 580, West 601 Walnut Street - Independence Square West,
Philadelphia, PA 19106-3304.
Dated: May 19, 2005.
Dennis Puccinelli,
Executive Secretary.
[FR Doc. 05-10461 Filed 5-24-05; 8:45 am]
BILLING CODE 3510-DS-S
